Compare · CYAN vs RGC
CYAN vs RGC
Side-by-side comparison of Cyanotech Corporation (CYAN) and Regencell Bioscience Holdings Limited (RGC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CYAN and RGC operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RGC is the larger of the two at $9.31B, about 535.0x CYAN ($17.4M).
- RGC has hit the wire 2 times in the past 4 weeks while CYAN has been quiet.
- Company
- Cyanotech Corporation
- Regencell Bioscience Holdings Limited
- Price
- $0.45-6.43%
- $19.04-2.88%
- Market cap
- $17.4M
- $9.31B
- 1M return
- -
- -28.52%
- 1Y return
- -
- -68.27%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 0
- 2
- Recent ratings
- 0
- 0
Cyanotech Corporation
Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company sells its products as packaged consumer products through distributors, retailers, and online channels, and direct to consumers, as well as in bulk form to manufacturers, formulators, and distributors. Cyanotech Corporation was incorporated in 1983 and is headquartered in Kailua-Kona, Hawaii.
Latest CYAN
- SEC Form 15-12G filed by Cyanotech Corporation
- Amendment: SEC Form SC 13E3/A filed by Cyanotech Corporation
- Amendment: SEC Form SC 13E3/A filed by Cyanotech Corporation
- SEC Form SC 13E3 filed by Cyanotech Corporation
- SEC Form 10-Q filed by Cyanotech Corporation
- Cyanotech Reports Financial Results for the Second Quarter of Fiscal 2026
- SEC Form 4 filed by CFO, VP Fin & Admin, Treasurer Miyashiro Jennifer A.S.
- SEC Form 3 filed by new insider Miyashiro Jennifer A.S.
- Director Mulder David M was granted 50,000 units of Cyanotech Corporation Common Stock, increasing direct ownership by 33% to 203,468 units (SEC Form 4)
- Director Vied David L was granted 50,000 units of Cyanotech Corporation Common Stock, increasing direct ownership by 29% to 225,138 units (SEC Form 4)
Latest RGC
- SEC Form 4 filed by Director Lo William Wing Yan Dr
- SEC Form 4 filed by Director Hui Evana Yee Wah
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 424B5 filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited